Table 1.
Participants’ characteristics
| ID# | Clinical diagnosis | Pathological diagnosis | Age at death (yrs) | Gender | PMI (hrs) | Braak & Braak (NFT) | CERAD score (neuritic plaques) | NIA-Reagan Institute criteria |
|---|---|---|---|---|---|---|---|---|
| #1 | CTL | Normal adult brain | 86 | M | 10 | I | none | LP |
| #2 | CTL | Normal adult brain | 73 | F | 20 | I | none | LP |
| #3 | CTL | Normal adult brain | 101 | F | 22 | II | A | LP |
| #4 | AD | AD | 96 | F | 20 | V | C | HP |
| #5 | AD | AD | 78 | F | 18 | VI | C | HP |
| #6 | AD | AD | 97 | F | 12 | VI | A | HP |
| #7 | AD | AD | 87 | F | 12 | IV | B | IP |
| #8 | AD | AD | 60 | M | 24 | VI | C | HP |
| #9 | AD | AD | 82 | F | 6 | V | B | HP |
| #10 | AD | AD | 69 | F | 4 | VI | C | HP |
| #11 | AD | AD | 70 | M | 6 | V | C | HP |
| #12 | AD | AD | 66 | F | 2 | VI | C | HP |
| #13 | AD | AD | 66 | F | 10 | VI | C | HP |
| #14 | AD | AD | 97 | F | 24 | V | C | HP |
| #15 | AD | AD | 81 | M | 7 | IV | C | IP |
| #16 | FTLD | AD/CAA | 66 | M | 16 | V | B | HP |
| #17 | Memory, speech and gait difficulties, hand tremor | Diffuse CAA (D23N Iowa APP mutation) | 45 | M | N/A | I | none | LP |
| #18 | AD | AD/Metastatic melanoma | 75 | M | 35 | V | B | IP |
| #19 | FTLD | PiD, type A | 61 | M | 19 | N/A | N/A | N/A |
| #20 | FTLD | PiD | 62 | M | 19 | I | A | LP |
| #21 | FTLD (P301L Mutation) | FTLD | 71 | F | 4 | I | none | LP |
| #22 | FTLD | DLDH | 65 | M | 24 | I | none | LP |
| #23 | CBD | CBD | 80 | M | 6 | I | none | LP |
| #24 | PSP | PSP | 69 | M | 45 | II | none | LP |
| #25 | PSP | PSP | 68 | M | 48 | II | none | LP |
| #26 | PSP | PSP | 78 | M | 11 | II | none | LP |
| #27 | PSP | PSP | 73 | M | 12 | II | none | LP |
| #28 | PSP | PSP | 63 | F | 12 | II | none | LP |
| #29 | CTE | CTE (CTE stage II-III) [23] | 25 | M | 27 | 0 | none | LP |
| #30 | CTE | CTE (CTE stage III) | 56 | M | N/A | II | none | LP |
| #31 | CTE | CTE (CTE stage III) | 46 | M | 72 | III | none | LP |
| #32 | CTE | CTE (CTE stage IV) | 65 | M | N/A | II | A | LP |
| #33 | CTE | CTE (CTE stage III) | 58 | M | N/A | III | none | LP |
| #34 | DLB | LBD | 62 | M | 24 | N/A | none | N/A |
| #35 | DLB | LBD, brainstem predominant | 76 | M | 17 | II | none | LP |
| #36 | PDD | LBD (Braak stage 4/6) | 83 | M | 9 | III | none | LP |
| #37 | MSA | MSA, cerebellar type (MSA-C) | 60 | F | 32 | II | none | LP |
| #38 | FTLD | FTLD-TDP-43, type A | 69 | F | 16 | I | none | LP |
| #39 | FTLD | FTLD-TDP-43 | 55 | M | 14 | I | none | LP |
| #40 | FTLD | FTLD-TDP-43 | 68 | M | 49 | I | none | LP |
| #41 | FTLD | FTLD-TDP-43 | 64 | M | 12 | I | none | LP |
| #42 | Headache | Subarachnoid hemorrhage | 92 | F | N/A | IV | A | IP |
| #43 | N/A | Parenchymal hemorrhage | 75 | M | N/A | I | none | LP |
Abbreviations: AD Alzheimer’s disease, APP amyloid precursor protein, CAA Cerebral amyloid angiopathy, CBD Corticobasal degeneration, CERAD Consortium to establish a registry for Alzheimer’s disease, CTL Control subject, DLB Dementia with lewy bodies, DLDH Dementia lacking distinctive histopathology, F Female, FTLD Frontotemporal lobar degeneration, HP High probability, IP Intermediate probability, LP Low probability, M Male, MSA Multiple systemic atrophy, NFT Neurofibrillary tangles, NIA National Institute of Aging, N/A Non available, PiD Pick’s disease, PMI Postmortem interval, PSP Progressive supranuclear palsy, TDP-43 TAR DNA binding protein 43